PARIS and CAMBRIDGE, Mass. — September 29, 2025 — Leads & Copy — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX) has announced updated data from cohorts 1 and 2 of Study 1100, which is evaluating JNJ-1900 (NBTXR3) activated by radiation therapy (RT) followed by anti-PD-1 immune checkpoint inhibitors (pembrolizumab or nivolumab; ICIs) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that is naïve (cohort 1) or resistant (cohort 2) to prior anti-PD-1 therapy. The results were presented at the 2025 Annual Meeting of the American Society of Radiation Oncology (ASTRO) by Study 1100 Coordinating Investigator Colette Shen, MD, PhD, Assistant Professor of Radiation Oncology, University of North Carolina Lineberger Comprehensive Cancer Center.
The treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-1.
In evaluable anti-PD-1 naïve patients per RECIST 1.1, a 63% disease control rate (DCR) and a 37% objective response rate (ORR) were achieved. For evaluable anti-PD-1 resistant patients per RECIST 1.1, DCR was 74% and ORR was 32%.
The median Overall Survival (mOS) in evaluable anti-PD-1 naïve patients was 15.5 months, while mOS in evaluable anti-PD-1 resistant patients was 11.4 months.
Investigators have concluded that these results warrant further exploration in randomized controlled trials.
Contact:
Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com
Source: Nanobiotix
